Access through your institution

通过您的机构访问

Buy or subscribe

购买或订阅

Patients with recurrent advanced-stage and/or metastatic cervical cancer typically have a poor prognosis with limited treatment options available. Now, data from the phase III innovaTV 301 trial demonstrate the efficacy of the tissue factor-targeted antibody–drug conjugate tisotumab vedotin in this setting.A total of 502 patients with advanced-stage and/or metastatic cervical cancer who previously received 1 (62.8%) or 2 (36.8%) lines of therapy were randomly assigned (1:1) to receive tisotumab vedotin versus investigator’s choice of chemotherapy (including topotecan, vinorelbine, gemcitabine, irinotecan or pemetrexed).

。现在，来自III期innovaTV 301试验的数据证明了组织因子靶向抗体-药物偶联物tisotumab vedotin在这种情况下的功效。共有502名先前接受过1（62.8%）或2（36.8%）治疗的晚期和/或转移性宫颈癌患者被随机分配（1:1）接受tisotumab vedotin与研究者选择的化疗（包括拓扑替康，长春瑞滨，吉西他滨，伊立替康或培美曲塞）。

Overall survival (OS) was the primary end point..

总生存期（OS）是主要终点。。

This is a preview of subscription content, access via your institution

这是订阅内容的预览，可通过您的机构访问

Access options

访问选项

Access through your institution

通过您的机构访问

Access through your institution

通过您的机构访问

Change institution

变革机构

Buy or subscribe

购买或订阅

Access Nature and 54 other Nature Portfolio journalsGet Nature+, our best-value online-access subscription24,99 € / 30 dayscancel any timeLearn moreSubscription info for Chinese customersWe have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.Go to naturechina.comBuy this articlePurchase on Springer LinkInstant access to full article PDFBuy nowPrices may be subject to local taxes which are calculated during checkout.

Access Nature和54篇其他Nature Portfolio journalsGet Nature+，我们最有价值的在线订阅24,99欧元/30天，随时为中国客户获取更多订阅信息我们为中国客户提供了一个专门的网站。请访问naturechina.com订阅本期刊。访问naturechina.comBuy本文在Springer link上购买即时访问完整文章PDFBuy now价格可能需要缴纳结帐时计算的地方税。

Additional access options:

其他访问选项：

Log in

登录

Learn about institutional subscriptions

了解机构订阅

Read our FAQs

阅读我们的常见问题

Contact customer support

联系客户支持

ReferencesOriginal articleVergote, I. et al. Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2313811 (2024)Download referencesAuthor informationAuthors and AffiliationsNature Reviews Clinical Oncology http://www.nature.com/nrclinoncPeter SidawayAuthorsPeter SidawayView author publicationsYou can also search for this author in.

参考文献Original articleVergote，I。等人Tisotumab vedotin作为复发性宫颈癌的二线或三线治疗。N、 英语。J、 医学。https://doi.org/10.1056/NEJMoa2313811（2024）下载参考文献作者信息作者和附属机构临床肿瘤学评论http://www.nature.com/nrclinoncPeter。

PubMed Google ScholarCorresponding authorCorrespondence to

PubMed谷歌学者通讯社

Peter Sidaway.Rights and permissionsReprints and permissionsAbout this articleCite this articleSidaway, P. Tisotumab vedotin effective in recurrent cervical cancer.

彼得·西达韦。权利和许可打印和许可本文引用本文Sidaway，P.Tisotumab vedotin对复发性宫颈癌有效。

Nat Rev Clin Oncol (2024). https://doi.org/10.1038/s41571-024-00929-4Download citationPublished: 22 July 2024DOI: https://doi.org/10.1038/s41571-024-00929-4Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

Nat Rev Clin Oncol（2024）。https://doi.org/10.1038/s41571-024-00929-4Download引文发布日期：2024年7月22日OI：https://doi.org/10.1038/s41571-024-00929-4Share本文与您共享以下链接的任何人都可以阅读此内容：获取可共享链接对不起，本文目前没有可共享的链接。复制到剪贴板。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供